A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Latest research shows how cannabis-derived medication helps Alzheimer's patients manage agitation, offering fresh hope to ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

I’m really annoyed, on behalf of the journalist Charles Piller, about the release date of his book “ Doctored: Fraud, ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

The UK announced the funding at the AI Action Summit in Paris where it abstained from signing a declaration on an inclusive ...

A neuroscientist whose published research has been embroiled in accusations of image manipulation and duplication has announced his resignation from the University of Minnesota, effective March 1. ...

NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...